1. Scrip
  2. >>Drug Pricing

ICER Suggests Price Of $2,500-$8,300 For Biogen’s Aducanumab

Cost Watchdog Sees Insufficient Data To Show Health Benefit

 
• By Mandy Jackson

Given mixed Phase III results for the Alzheimer’s drug and potentially severe side effects for the once-monthly infused therapy, ICER’s recommendation came in below analyst expectations.

The old man leaves the road among the trees. Alzheimer's disease and withdrawal from life.
ICER said aducanumab's benefit in Alzheimer's disease is unclear • Source: Alamy

The Institute for Clinical and Economic Review (ICER) issued a draft evidence report on the effectiveness and value of Biogen, Inc.’s amyloid-clearing antibody aducanumab for mild Alzheimer’s disease with a recommended price of $2,500-$8,300 per year, which fell short of analyst predictions. ICER said the available data for aducanumab are insufficient to determine the net health benefit for patients given mixed Phase III efficacy results and the high risk of a potentially serious side effect.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.